89 results about "Tolvaptan" patented technology

The invention relates to a preparation method of benzazepine compounds, particularly a preparation method of 7-chloro-2,3,4,5-tetrahydro-1H-1-benzazepino-5-ketone. The 7-chloro-2,3,4,5-tetrahydro-1H-1-benzazepino-5-ketone can be used as an intermediate for preparing a pitressin antagonist medicament Tolvaptan. The method comprises the following steps: by using parachloroaniline as a raw material, reacting with paratoluensulfonyl chloride in a condensation mode under the alkaline condition to firstly protect amino groups; under the alkaline condition, coupling with ethyl 4-bromobutyrate to obtain a compound; in the presence of alkali, hydrolyzing the obtained compound, and acidifying; in dichloromethane, preparing acyl chloride from the acidified compound under the action of thionyl chloride; under the action of Lewis acid, carrying out Friedel-Crafts acylation reaction to perform intramolecular cyclization; and finally, removing tosyl groups to obtain the target product. The invention has the advantages of simple technique and low cost, and is convenient for industrial large-scale production.

The invention provides a tolvaptan solid preparation. The solid preparation is prepared from tolvaptan amorphous composition which is prepared by dissolving and drying tolvaptan and a carrier, as well as other pharmaceutically acceptable auxiliary materials, wherein the weight ratio of tolvaptan to the carrier is between 1:1.5 and 1:5. The preparation has the advantages of good solubility, good stability and high bioavailability.

The invention provides a method for preparing tolvaptan intermediate 7-chloro-1-[2-methyl-4-(2-methylbenzoylamino)-benzoyl]2,3,4,5-tetrahydro-1H-1-benzazepine-5-ketone, which comprises the following steps of: reacting a general formula (3) with thionyl chloride to form acetyl chloride solution; and then performing amidation reaction on a general formula (2) and the acetyl chloride solution in an organic solvent in the presence of de-acidifying agent, and treating the reaction product to obtain the tolvaptan intermediate shown in a general formula (1). The tolvaptan intermediate prepared by adopting the method of the invention has the characteristics of low cost, little impurity and high yield, and is more suitable for large-scale industrialized production.

The invention relates to a tolvaptan medicinal composition and a preparation method thereof. 1,000 tablets of the composition consist of 15 to 60 grams of tolvaptan, 15 to 60 grams of hydroxypropyl-beta-cyclodextrin, 30 to 120 grams of microcrystalline cellulose with pH of 102, 10 to 40 grams of cross-linked polyvinylpyrrolidone, 10 to 40 grams of pregelatinized starch, 20 to 80 grams of lactose and 1 to 10 grams of magnesium stearate. In the preparation method, the conventional preparation technology is adopted after the tolvaptan and the hydroxypropyl-beta-cyclodextrin are subjected to special processing. The prepared tolvaptan medicinal composition has the advantages of high fluidity, high dissolution, small tablet weight variation, high stability, high biological utilization degree and good therapeutic effect.

The invention relates to a preparation method for 7-chlorine-5-oxo-2,3,4,5-tetrahydro-1H-1-benzoazepine. The 7-chlorine-5-oxo-2,3,4,5-tetrahydro-1H-1-benzoazepine is an important intermediate for preparing arginine pitressin V2 receptor antagonist Tolvaptan. In the preparation method, the target product 7-chlorine-5-oxo-2,3,4,5-tetrahydro-1H-1-benzoazepine is prepared by removing tosyl and carbalkoxy from 7-chlorine-5-oxo-4-carbalkoxy-1-tosyl-2,3,4,5-tetrahydro-1-benzoazepine serving as a raw material under the action of sulfuric acid and by a 'one-pot method'. The sulfuric acid is used for performing 'one-pot method' reaction, so reaction steps are reduced and reaction time is greatly shortened. The preparation method has the advantages of simpleness and convenience for operation, equipment and cost saving, simpleness and practicability in separation and purification, short reaction time, high yield and high product purity and is applicable to industrialized production.

The invention provides a tolvaptan oral solid medicinal composition. The tolvaptan oral solid medicinal composition is prepared from the following components in percentage by weight: 3 to 50 percent of tolvaptan, 1 to 10 percent of adhesive, 20 to 80 percent of hydrophilic carrier, 0 to 20 percent of disintegrant, 5 to 60 percent of filler, 0 to 5 percent of flow aid, and 0.1 to 3.0 percent of lubricant. The tolvaptan medicinal composition is an oral solid preparation and is preferably tablets and capsules. The invention also provides a method for preparing the medicinal composition. The tolvaptan oral solid medicinal composition has good disintegration performance and dissolution performance; the composition has lower impurity content and is steadier; the preparation process is simple and easy; and the method is suitable for industrialized mass production.

The invention discloses a preparation method of tolvaptan. According to the preparation method, 7-chloro-1,2,3,4-tetrahydrobenzo[b]azepine-5-one and 4-nitro-2-methyl bromobenzene are taken as the primary raw materials; high purity tolvaptan is obtained after steps of carbonyl inserting reactions, reduction reactions, and acylation reactions, and the yield is high. The preparation method has the advantages that no bromine or tin dichloride is used; the preparation method does not generate a large amount of industrial waste water, and the environment is protected. At the same time, the generation of impurities namely a compound V and a compound VIII is avoided, and the purification becomes easier. No explosive, flammable, and toxic solvent such as chloroform, ether, and the like, is used, the requirements on the protection of workers are lowered, and the safe production is guaranteed. Moreover, the route design is novel, the raw materials are easily available, the operation of the technology is simple and feasible, and a simple and feasible method is provided for the massive industrial production of tolvaptan.

The invention discloses a preparation method of tolvaptan. The method is characterized in that tolvaptan is obtained through an amidation reaction of 7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1H-1-benzoaza and 2-methyl-4-(2-methylphenylamido)benzoyl chloride. The method has the advantages of novel design, work time efficiency increase, reduction of waste liquid discharge, simple operation, easily available raw materials, simple post-treatment and high yield, and is suitable for industrial production.

The invention provides a preparation method for a cardiovascular disease treatment drug. Specifically, the invention provides a compound represented by a formula (IV) shown in the description and a method for preparing Tolvaptan from the compound represented by the formula (IV). The method provided by the invention has the advantages of being environment-friendly, being easy in raw material obtaining and high in total yield, and the like, thereby being applicable to the industrialized preparation of Tolvaptan.

An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.

The invention relates to the field of pharmaceutical chemistry and particularly discloses preparation methods for a tolvaptan intermediate 1-(4-amino-2-methylbenzoyl)-7-chloro-5-oxo-2,3,4,5-tetrahydro-1H-1-benzoazepine (I) (shown in the description) and salts thereof. The tolvaptan intermediate prepared by utilizing the method disclosed by the invention has the characteristics of low cost, high yield, environmental friendliness, strong operability and suitability for industrial production.

The invention discloses a preparation method of high-purity tolvaptan. The preparation method comprises the step of reducing N-[4-[(5R)-7-chloro-5-oxo-2,3,4,5-tetrahydro-1-benazepine-1-formyl]-3-methyl phenyl]-2-methyl benzamide with sodium bis(2-methoxyethoxy) aluminumhydride, thereby obtaining the high-purity tolvaptan with the purity higher than or equal to 99.95%. The preparation method disclosed by the invention has the advantages that sodium bis(2-methoxyethoxy) aluminumhydride is adopted as a reducing agent for preparing tolvaptan by reducing N-[4-[(5R)-7-chloro-5-oxo-2,3,4,5-tetrahydro-1-benazepine-1-formyl]-3-methyl phenyl]-2-methyl benzamide, the production of a dechlorination impurity IV can be extremely effectively inhibited, and finally the high-purity tolvaptan with the purity higher than or equal to 99.95% can be obtained, and high yield being 90% or above can be obtained while tetrahydrofuran or methyltetrahydrofuran is adopted as a reaction solvent.

The invention discloses a preparation method of a tolvaptan tablet. The preparation method comprises the following steps: 1, mixing tolvaptan with high-substituted hydroxylpropyl cellulose according to a mass ratio of 1:0.2-0.6, crushing them, and sieving by a 60-100 mesh sieve; 2, dissolving throughs in a mixed solution of waterless ethanol and dichloromethane with a volume ratio of 1:1-4, carrying out spray drying to form powder, carrying out reduced pressure drying at 70-90DEG C until that the content of solvents residual in the sprayed powder is qualified; 3, crushing the sprayed powder, sieving by a 180-220 mesh sieve, accurately weighing the sprayed powder, lactose, microcrystalline cellulose and hydroxypropyl methylcellulose according to prescription amounts, uniformly mixing them, and adding a proper amount of water to prepare a soft material; and 4, sieving the soft material by a 15-25 mesh sieve, preparing a wet particle, drying the wet particle at 50-70DEG C until that the content of water in the wet particle is 2-4%, sieving the dried wet particle by a 15-25 mesh sieve, granulating, adding a prescription amount of magnesium stearate, uniformly mixing, and tabletting. The preparation method of the invention has the advantages of ingenious conception, low production cost, high in vitro dissolubility of the prepared tolvaptan tablet, and good biological availability and clinic curative effect of the tolvaptan tablet.

The present invention relates to a kind of tolvaptan tablet, and the invention belongs to the new technical field of medicine manufacturing, specifically relates to tolvaptan tablet and a kind of preparation method thereof, and this tablet is tolvaptan as main component, is produced by tolvaptan Protan solid dispersion granules and auxiliary materials are directly compressed into tablets. The tolvaptan tablet of the invention solves the problem of in vitro dissolution of the tolvaptan, improves the curative effect of the drug, and has a more ideal therapeutic effect.

The invention discloses a medicinal solid preparation containing tolvaptan and a preparation method. The preparation method comprises steps of converting active pharmaceutical ingredients of tolvaptaninto amorphous forms by spray-drying. The preparation method is characterized by controlling the amorphous solid dispersible powder to be 35-80 [mu]m in particle size D90. The preparation method alsocomprises steps of adding lactose, corn starch, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, magnesium stearate and other auxiliary materials, and conducting granulation through a fluidized bed to obtain the medicinal solid preparation of tolvaptan with good in-vivo solubility and high bioavailability.

The invention relates to a method for preparing a tolvaptan intermediate, namely 7-chlorine-5-oxo-1-(2-methyl-4-nitrobenzene formyl)-1,2,3,4-tetrahydro-benzo-azepine. The tolvaptan intermediate which is a compound as shown in the formula (1) is obtained by 7-chlorine-5-oxo-2,3,4,5-tetrahydro-1H-1-benzo-azepine (2) reacting with 4-nitryl-2-methylbenzene formyl chloride (3). The tolvaptan intermediate prepared by the method has the advantages of high purity, high yield and short reaction time, thereby being suitable for large-scale industrialized production.

The invention discloses a tolvaptan preparation containing micronized tolvaptan and water-soluble auxiliary materials, each tablet contains tolvaptan 7.5mg-60mg and the 90% cumulative particle size of tolvaptan is not greater than 75 microns; Each tablet contains no more than 60% of the weight of the tablet, and the weight-number ratio of tolvaptan to the water-soluble auxiliary material is 1:2.5-1:10. The invention solves the problem of poor compliance of the tolvaptan tablet during use, and provides a new alternative excellent dosage form for clinical use.

The invention discloses a method for preparing amorphous tolvaptan. The method comprises the steps of dissolving a tolvaptan crystalline compound into a solvent I, cooling to the temperature of 25-40 DEG C, so as to obtain a tolvaptan solution, then, adding the obtained tolvaptan solution into a rapidly-stirred solvent II, continuing to stir for 5-15 minutes after the adding is completed, then, filtering and drying, thereby obtaining amorphous tolvaptan, wherein the weight/volume ratio of the tolvaptan crystalline compound to the solvent I is 1g: (5-50)mL, solid precipitation exists during adding, the dosage of the solvent II is 0.5-5 times that of the solvent I, and the temperature of the rapidly-stirred solvent II is kept at 0-5 DEG C. According to the method, through using different solvents respectively at a dissolution stage and a precipitation stage and controlling the temperature change and dosage of the solvents, the yield of amorphous tolvaptan can be higher; moreover, the method disclosed by the invention is simple, is easy in operation and has no need of using large-sized equipment, such as a fluidized bed and the like, thereby being capable of playing a more active role in popularizing the drug.

The invention discloses a preparation method of tolvaptan key intermediate 7-chloro-5-oxo-1,2,3,4-tetrahydro-benzazepine. The preparation method comprises the steps of condensing parachloroaniline, which is taken as a starting raw material, with 4-chlorobutyric acid methyl ester, carrying out hydrolysis de-esterification and acylating chlorination, and carrying out ring closure under an acidic condition, so as to obtain a target product, wherein the total yield of the target product can reach above 80%, and the HPLC (High Performance Liquid Chromatography) purity reaches above 99.5%.

The invention discloses a tolvaptan crystal containing 0.5 crystal water. The crystal has a tolvaptan crystal powder X-ray diffraction pattern represented by a figure 1, a differential scanning calorimetry (DSC) analytical figure represented by the figure 2, and characteristics shown in an infrared spectrum represented by a figure 4. Meanwhile, the invention further discloses 1-100mg of a medicine composition composed of a tolvaptan crystal contains 0.5 crystal water, and one or more pharmaceutically acceptable medicinal carriers. The tolvaptan crystal containing 0.5 crystal water is advantaged in simple preparation technology, good reproducibility, and easy drying. The crystal is stable to light, heat, and humidity. The crystal is suitable for long-time storage, and is suitable for large-scale productions.

The invention discloses a 7-chloro-5-oxo-2, 3, 4, 5-tetrahydro-1H-1-benzoazepine carboxylic ester compound, its preparation method, and a method of utilizing the compound to prepare another tolvaptan intermediate 7-chloro-5-oxo-2, 3, 4, 5-tetrahydro-1H-1-benzoazepine. The 7-chloro-5-oxo-2, 3, 4, 5-tetrahydro-1H-1-benzoazepine prepared by the method provided in the invention has a high yield, and can be prepared by a one-pot process, thus greatly simplifying the reaction operation. Also, the used materials and reagents are cheap and commercially available, the reaction is mild and environment-friendly, so that the method is suitable for large-scale production.

The invention discloses a solid medicine composition of tolvaptan. The solid medicine composition of tolvaptan comprises granular or unformed powder of tolvaptan, sugar and a sugar alcohol diluent. The preparation method comprises the following steps of: highly dispersing the active component tolvaptan into the diluent to obtain solid dispersoid; and preparing into oral solid preparation with pharmaceutically acceptable auxiliary materials. The solid medicine composition is clinically used for treating hyponatremia.

This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan from the gastrointestinal tract; and a solid formulation for oral administration that can be suspended to prepare the suspension for oral administration at the time of use. This invention relates to a suspension for oral administration, in particular, a syrup, comprising (a) particles containing amorphous tolvaptan, (b) hydroxypropyl methylcellulose (HPMC), and (c) a solvent, wherein the amount of the HPMC (b) is 0.1 to 25% by weight based on the total weight of the suspension for oral administration.

The invention belongs to the field of drug synthesis, and particularly relates to a preparation method of a tolvaptan intermediate 7-chloro-2,3,4,5,10,11-hexahydro-1H-1-benzodiazepines-5-one. The method comprises the following steps: by taking N-vinylpyrrolidone as an active ingredient, rearranging under light to obtain 4-azecycloheptatrienone, then protecting nitrogen methyl p-toluenesulfinate, reacting with 2-chloro-2-butenal in the presence of diaryl D-prolinol derivatives to generate 7-chloro-2,3,4,5,10,11-hexahydro-1H-1-benzodiazepines-5-one, dehydrogenizing and aromatizing in the presence of manganese dioxide, and finally removing protection groups to obtain the 7-chloro-2,3,4,5,10,11-hexahydro-1H-1-benzodiazepines-5-one. Due to no Claisen condensation or Friedle-Crafts reaction in the conventional synthesis method, the potassium tert-butanol and aluminum trichloride are omitted, the preparation method is mild in reaction conditions, easily available in raw materials, capable of lowering the cost, and more suitable for industrial production.